Monitoring the redox status in multiple sclerosis
Worldwide, over 2.2 million people suffer from multiple sclerosis (MS), a multifactorial
demyelinating disease of the central nervous system. MS is characterized by a wide range of …
demyelinating disease of the central nervous system. MS is characterized by a wide range of …
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
R Liu, S Du, L Zhao, S Jain, K Sahay… - Frontiers in …, 2022 - frontiersin.org
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS) characterized by destruction of the myelin sheath structure. The loss of myelin leads …
(CNS) characterized by destruction of the myelin sheath structure. The loss of myelin leads …
Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
Introduction Interferon beta (IFN beta) preparations are an established group of drugs used
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
Eighty-five percent of multiple sclerosis cases begin with a discrete attack termed clinically
isolated syndrome, but 37% of clinically isolated syndrome patients do not experience a …
isolated syndrome, but 37% of clinically isolated syndrome patients do not experience a …
Re-evaluating the use of IFN-β and relapsing multiple sclerosis: safety, efficacy and place in therapy
CH Goldschmidt, LH Hua - Degenerative Neurological and …, 2020 - Taylor & Francis
The advent of interferon therapy for the treatment of multiple sclerosis (MS) was a massive
advancement in the field and changed the course of the disease. While the exact …
advancement in the field and changed the course of the disease. While the exact …
Gene therapy approaches in an autoimmune demyelinating disease: multiple sclerosis
Multiple Sclerosis (MS) is the most common autoimmune demyelinating disease of the
Central Nervous System (CNS). It is a multifactorial disease which develops in an immune …
Central Nervous System (CNS). It is a multifactorial disease which develops in an immune …
Preparation, characterization and in-vivo efficacy study of glatiramer acetate (GA)-hydrogel-microparticles as novel drug delivery system for GA in RRMS
Abstract Relapsing Remitting Multiple Sclerosis is a chronic Central nervous system
autoimmune disease. There is no absolute treatment for MS and the available remedies are …
autoimmune disease. There is no absolute treatment for MS and the available remedies are …
NetConfer: a web application for comparative analysis of multiple biological networks
Background Most biological experiments are inherently designed to compare changes or
transitions of state between conditions of interest. The advancements in data intensive …
transitions of state between conditions of interest. The advancements in data intensive …
Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering …
K Karampampa, H Gyllensten, E Friberg, C Murley… - BMJ open, 2023 - bmjopen.bmj.com
Objectives Disease-modifying therapies (DMTs) can slow disease progression in multiple
sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) …
sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) …
Treatment response score to glatiramer acetate or interferon beta-1a
Objective To compare the effectiveness of glatiramer acetate (GA) vs intramuscular
interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at …
interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at …